65,437 trials
Breast Cancer
Primary: Number of Breasts With Successful Tissue Expansion With Exchange to a Permanent Breast Implant Unless Exchange is Precluded by a Non-device Related Event — 80 breasts
Erosive Esophagitis
Primary: The Rates of Complete Symptom Relief — 152; 157 participants — p=<0.05
Focus of Study of Healthy Adults
Primary: Peak Plasma Nitrate Concentration Over 24 Hour Study Period — 769; 41 microMolar (microM)
Lung Cancer
Primary: Objective Response Rate (ORR) — 7.69 percentage of participants
Diabetic Gastroparesis
Primary: Hypoglycemic Episodes — 1.9; 2.2 event rate per person-week — p=<0.0001
Rheumatoid Arthritis
Primary: Percentage of Participants on Tocilizumab Treatment at Month 6 After Treatment Initiation — 79.4 percentage of participants
Obesity
Primary: Change in Insulin Sensitivity- Pre-roflumilast — 48.7 mg/grams Fat Free Mass/minute
Irritable Bowel Syndrome
Primary: Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores — 23.9…
Prostate Cancer
Primary: Overall Survival — 87; 86 percentage of probability of survival — p=0.70
Ocular Hypertension · Open Angle Glaucoma
Primary: 24 Hour IOP — 23.55; 21.77 mm Hg — p=<0.001
Herniated Lumbar Disc
Primary: Pain Assessed by Visual Analogue Scale — 5.63; 5.92 units on a scale
Hyperhidrosis
Primary: Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4 — 10; 10; 9; 10 Participants
Rheumatoid Arthritis
Primary: The Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Improvement — 10; 16; 19; 16 Participants — p=0.0619
Autism
Primary: Test of Adolescent Social Skills Knowledge (TASSK) — 8; 3.5 score on a scale
Cystic Fibrosis
Primary: Change in FEV1 % Predicted From Baseline — -0.1; 1.4 percentage of predicted — p=<0.05